This is massive news! I dont have access to the full article, but here is a quick summary
"Japanese drug major Astellas Pharma (TYO: 4503) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Vyloy (zolbetuximab), an anti-claudin 18.2 (CLDN18.2) monoclonal antibody for patients with CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. Astellas noted that this makes Vyloy is the first and only CLDN18.2-targeted therapy approved by any regulatory agency in the world.
Why is this such big news?
https://www.thepharmaletter.com/article/astellas-gets-first-approval-for-vyloy-in-japan?mc_cid=b0fef19e05
https://www.pharmaceutical-technology.com/news/astellas-secures-approval-for-gastric-cancer-antibody-in-japan/?cf-view
- Forums
- ASX - By Stock
- Astellas gets first approval for Vyloy, in Japan
ALA
arovella therapeutics limited
Add to My Watchlist
2.13%
!
9.2¢

This is massive news! I dont have access to the full article,...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.2¢ |
Change
-0.002(2.13%) |
Mkt cap ! $109.7M |
Open | High | Low | Value | Volume |
9.2¢ | 9.5¢ | 9.0¢ | $120.5K | 1.312M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 54053 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.3¢ | 29358 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4053 | 0.092 |
4 | 67325 | 0.091 |
4 | 632880 | 0.090 |
3 | 51179 | 0.089 |
2 | 72000 | 0.088 |
Price($) | Vol. | No. |
---|---|---|
0.093 | 29358 | 2 |
0.094 | 118372 | 2 |
0.095 | 4999 | 1 |
0.096 | 12000 | 1 |
0.097 | 47888 | 1 |
Last trade - 12.26pm 13/08/2025 (20 minute delay) ? |
Featured News
ALA (ASX) Chart |